Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine

The presence of multiple subclones within tumors mandates understanding of longitudinal and spatial subclonal dynamics. Resolving the spatial and temporal heterogeneity of subclones with cancer driver events may offer insight into therapy response, tumor evolutionary histories and clinical trial design.

• Publication year

  2014

• Venue

  Genome Biology

• Publication date

  2014-08-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s13059-014-0453-8PMID 25222836PMCID 4281956
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

  2014cited by this paper
• Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

  2014cited by this paper
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  2014cited by this paper
• Mutational context and diverse clonal development in early and late bladder cancer.

  2014cited by this paper
• Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

  2014cited by this paper
• Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

  2014cited by this paper
• Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

  2014cited by this paper
• PyClone: statistical inference of clonal population structure in cancer

  2014cited by this paper
• Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance.

  2014cited by this paper
• MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.

  2014cited by this paper
• Punctuated evolution of prostate cancer genomes.

  2013cited by this paper
• Lung cancer chemoprevention: current status and future prospects

  2013cited by this paper
• Addressing genetic tumor heterogeneity through computationally predictive combination therapy.

  2013cited by this paper
• Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.

  2013influential reference
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• The causes and consequences of genetic heterogeneity in cancer evolution

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• Clinical and biological implications of driver mutations in myelodysplastic syndromes.

  2013cited by this paper
• Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications

  2013cited by this paper
• Lessons from the cancer genome.

  2013cited by this paper
• Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion

  2013cited by this paper
• Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

  2013cited by this paper
• An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

  2013cited by this paper
• Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling

  2013cited by this paper
• Cancer drug resistance: an evolving paradigm

  2013cited by this paper
• Designing transformative clinical trials in the cancer genome era.

  2013cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• Molecular mechanisms of cisplatin resistance

  2012cited by this paper
• The road to resistance: EGFR mutation and cetuximab

  2012cited by this paper
• The Life History of 21 Breast Cancers

  2012cited by this paper
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

  2012cited by this paper
• Mutational Processes Molding the Genomes of 21 Breast Cancers

  2012cited by this paper
• Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.

  2012cited by this paper
• Intratumor Heterogeneity: Seeing the Wood for the Trees

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Absolute quantification of somatic DNA alterations in human cancer

  2012cited by this paper
• Detection of ultra-rare mutations by next-generation sequencing

  2012cited by this paper
• The clonal and mutational evolution spectrum of primary triple-negative breast cancers

  2012cited by this paper
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012influential reference
• Clonal architecture of secondary acute myeloid leukemia.

  2012cited by this paper
• Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

  2012cited by this paper
• Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer

  2011cited by this paper
• Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

  2011cited by this paper
• Genetic variegation of clonal architecture and propagating cells in leukaemia

  2011influential reference
• Temporal dissection of tumorigenesis in primary cancers.

  2011cited by this paper
• Detection and quantification of rare mutations with massively parallel sequencing

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer

  2011cited by this paper
• Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

  2011cited by this paper
• Tumour evolution inferred by single-cell sequencing

  2011cited by this paper
• The patterns and dynamics of genomic instability in metastatic pancreatic cancer

  2010cited by this paper
• Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

  2010cited by this paper
• RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF

  2010cited by this paper
• Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer

  2010influential reference
• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

  2010cited by this paper
• Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

  2010cited by this paper
• Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

  2010cited by this paper
• Tracing the tumor lineage

  2010cited by this paper
• Clonal evolution in cancer

  2010cited by this paper
• PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data

  2009cited by this paper
• Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.

  2009cited by this paper
• Adaptive therapy.

  2009cited by this paper
• Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia

  2008cited by this paper
• Epistasis — the essential role of gene interactions in the structure and evolution of genetic systems

  2008cited by this paper
• Cancer as an evolutionary and ecological process

  2006cited by this paper
• A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

  2006cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper

• Identifying and Characterising Response in Clinical Trials: Development and Validation of a Machine Learning Approach in Colorectal Cancer

  2026cites this paper
• Habitat image based on enhanced MRI before transcatheter arterial chemoembolization of hepatocellular carcinoma clinical value of prognosis prediction

  2025cites this paper
• DNA repair and the contribution to chemotherapy resistance

  2025cites this paper
• Application value of different imaging methods in the early diagnosis of small hepatocellular carcinoma: a network meta-analysis

  2025cites this paper
• Advancements in MRI radiomics for hepatocellular carcinoma: a narrative review

  2025cites this paper
• Single-cell copy number alteration signature analysis reveals masked patterns and potential biomarkers for cancer

  2025cites this paper
• Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations

  2025cites this paper
• Cancer Stem Cells; More Cancer or Stem?

  2025cites this paper
• The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial

  2025cites this paper
• Dissecting Tumor Heterogeneity by Liquid Biopsy—A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid Neoplasias

  2025cites this paper
• The reckoning of chromosomal instability: past, present, future

  2024cites this paper
• Coefficient of Variation in Metastatic Lymph Nodes Determined by 18F-FDG PET/CT in Patients with Advanced NSCLC: Combination with Coefficient of Variation in Primary Tumors

  2024cites this paper
• STARD7 could be an immunological and prognostic biomarker: from pan-cancer analysis to hepatocellular carcinoma validation

  2024cites this paper
• Imaging Genomics of Glioma Revisited: Analytic Methods to Understand Spatial and Temporal Heterogeneity

  2024cites this paper
• Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC

  2024cites this paper
• Review and prospects of new progress in intelligent imaging research on lymph node metastasis in esophageal carcinoma

  2024cites this paper
• A novel liquid biopsy assay for detection of ERBB2 (HER2) amplification in circulating tumor cells (CTCs)

  2024cites this paper
• Targeted therapies in advanced biliary malignancies: a clinical review

  2024cites this paper
• Systematic data analysis pipeline for quantitative morphological cell phenotyping

  2024cites this paper
• Low-pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple-negative breast cancer

  2024cites this paper
• Feasibility Study of Computed Tomographic Radiomics Model for the Prediction of Early and Intermediate Stage Hepatocellular Carcinoma Using BCLC Staging

  2024cites this paper
• Whole‐exome sequencing‐based mutational profiling of hepatocellular adenoma malignant transformation to hepatocellular carcinoma

  2024cites this paper
• Clinical trial designs for evaluating and exploiting cancer evolution.

  2023cites this paper
• Contrary to known silibinin is not an anticancer agent and liver protective supplement

  2023cites this paper
• Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal

  2023cites this paper
• Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer.

  2023cites this paper
• Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.

  2023cites this paper
• ConDoR: Tumor phylogeny inference with a copy-number constrained mutation loss model

  2023cites this paper
• The nature of cancer

  2023cites this paper
• Blood-based liquid biopsy in advanced prostate cancer.

  2023cites this paper
• Single-Cell Evolutionary Analysis Reveals Drivers of Plasticity and Mediators of Chemoresistance in Small Cell Lung Cancer.

  2023cites this paper
• Biopsias líquidas en cáncer: ¿estamos preparados para remplazar el tejido tumoral?

  2023cites this paper
• Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer

  2023cites this paper
• Preoperative CT radiomics of esophageal squamous cell carcinoma and lymph node to predict nodal disease with a high diagnostic capability.

  2023cites this paper
• ConDoR: tumor phylogeny inference with a copy-number constrained mutation loss model

  2023cites this paper
• Spatial mapping of tumor heterogeneity in whole-body PET–CT: a feasibility study

  2023cites this paper
• Editorial: The role of multi-omics variants in tumor immunity and immunotherapy

  2022cites this paper
• Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers.

  2022cites this paper
• Multi-staged gene expression profiling reveals potential genes and the critical pathways in kidney cancer

  2022cites this paper
• Roles of circulating tumor DNA in PD-1/PD-L1 immune checkpoint Inhibitors: Current evidence and future directions.

  2022cites this paper
• Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians

  2022cites this paper
• Single Cell lineage Tracing Identifies Cancer Testis Antigens as Mediators of Chemoresistance in Small Cell Lung Cancer

  2022influential citation
• A new machine learning method for cancer mutation analysis

  2022cites this paper
• Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

  2022cites this paper
• Microfluidics for detection of exosomes and microRNAs in cancer: State of the art

  2022cites this paper
• Yeast-based evolutionary modeling of androgen receptor mutations and natural selection

  2022cites this paper
• Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer

  2022cites this paper
• Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology

  2022cites this paper
• 18F-FDG PET/CT radiomic analysis for classifying and predicting microvascular invasion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma

  2022cites this paper
• Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma

  2022cites this paper
• When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review

  2021cites this paper
• Mutation and expression alterations of histone methylation-related NSD2, KDM2B and SETMAR genes in colon cancers.

  2021cites this paper
• Cancer evolution: Darwin and beyond

  2021cites this paper
• Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Advanced Biliary Tract Cancer

  2021cites this paper
• Progress of MRI Radiomics in Hepatocellular Carcinoma

  2021cites this paper
• Quantification of tumor heterogeneity: from data acquisition to metric generation.

  2021cites this paper
• Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes

  2021cites this paper
• Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients

  2021cites this paper
• AI-Driver: an ensemble method for identifying driver mutations in personal cancer genomes

  2020cites this paper
• Radiomics in Hepatocellular Carcinoma

  2020cites this paper
• EGFR and BRAF mutations in inverted sinonasal papilloma — a more complex landscape?

  2020cites this paper
• Radiomics in Hepatocellular Carcinoma

  2020cites this paper
• Extracellular Vesicles as Biomarkers in Cancer Immunotherapy

  2020cites this paper
• Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.

  2020cites this paper
• Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

  2020cites this paper
• The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer

  2020cites this paper
• Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling.

  2020cites this paper
• Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology

  2020cites this paper
• Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study

  2020cites this paper
• Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.

  2019cites this paper
• Die Untersuchung zellfreier DNA durch Liquid Biopsy in der Medizin

  2019cites this paper
• Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer.

  2019cites this paper
• Imaging Phenotypes of Breast Cancer Heterogeneity in Preoperative Breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Scans Predict 10-Year Recurrence

  2019cites this paper
• Assessing the Concordance of Genomic Alterations between Circulating-Free DNA and Tumour Tissue in Cancer Patients

  2019cites this paper
• 1 Cancer stem cells in Osteosarcoma

  2019cites this paper
• Polytherapy and Targeted Cancer Drug Resistance.

  2019cites this paper
• Circulating tumor DNA and their added value in molecular oncology

  2019cites this paper
• Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies

  2019cites this paper
• Improving Outcomes in Prostate Cancer

  2019cites this paper
• Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma

  2019cites this paper
• PRISM: methylation pattern-based, reference-free inference of subclonal makeup

  2019cites this paper
• Maximum allele frequency observed in plasma: A potential indicator of liquid biopsy sensitivity.

  2019cites this paper
• Rational "Error Elimination" Approach to Evaluating Molecular Barcoded Next-Generation Sequencing Data Identifies Low-Frequency Mutations in Hematologic Malignancies.

  2019cites this paper
• Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator

  2019cites this paper
• TP53, EGFR and PIK3CA gene variations observed as prominent biomarkers in breast and lung cancer by plasma cell-free DNA genomic testing.

  2019cites this paper
• Radiomics in hepatocellular carcinoma: a quantitative review

  2019cites this paper
• Biological variables and their potential impact on biomarkers and precision medicine initiative

  2019cites this paper
• Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers

  2018cites this paper
• Finding driver mutations in cancer: Elucidating the role of background mutational processes

  2018cites this paper
• Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity

  2018cites this paper
• Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  2018cites this paper
• Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes

  2018cites this paper
• Differentiation of Predominantly Solid Enhancing Lipid-Poor Renal Cell Masses by Use of Contrast-Enhanced CT: Evaluating the Role of Texture in Tumor Subtyping.

  2018cites this paper
• Genomic Evolution of Chemoresistance in Triple-Negative Breast Cancer Delineated by Single Cell Sequencing

  2018cites this paper
• An optimized prediction framework to assess the functional impact of pharmacogenetic variants

  2018cites this paper
• 如何认识和处理肿瘤异质性

  2018cites this paper
• Significance of Intratumoral Fibrosis in Clear Cell Renal Cell Carcinoma

  2018influential citation
• Timing somatic events in the evolution of cancer

  2018cites this paper
• Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform

  2018cites this paper
• Prognostic Significance of EPHB2 Expression in Colorectal Cancer Progression

  2018cites this paper